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The objective of this study was to evaluate the pharmacokinetics of voriconazole and the potential correlations
between pharmacokinetic parameters and patient variables in liver transplant patients on a fixed-dose prophylactic
regimen. Multiple blood samples were collected within one dosing interval from 15 patients who were initiated on
a prophylactic regimen of voriconazole at 200 mg enterally (tablets) twice daily starting immediately posttransplant.
Voriconazole plasma concentrations were measured using high-pressure liquid chromatography (HPLC). Noncom-
partmental pharmacokinetic analysis was performed to estimate pharmacokinetic parameters. The mean apparent
systemic clearance over bioavailability (CL/F), apparent steady-state volume of distribution over bioavailability
(Vss/F), and half-life (t1/2) were 5.8 5.5 liters/h, 94.5 54.9 liters, and 15.7 7.0 h, respectively. There was a good
correlation between the area under the concentration-time curve from 0 h to infinity (AUC0-) and trough
voriconazole plasma concentrations. t1/2, maximum drug concentration in plasma (Cmax), trough level, AUC0-,
area under the first moment of the concentration-time curve from 0 h to infinity (AUMC0-), and mean residence
time from 0 h to infinity (MRT0-) were significantly correlated with postoperative time. t1/2, , AUC0-, and CL/F
were significantly correlated with indices of liver function (aspartate transaminase [AST], total bilirubin, and
international normalized ratio [INR]). The Cmax, last concentration in plasma at 12 h (Clast), AUMC0-, and
MRT0- were significantly lower in the presence of deficient CYP2C19*2 alleles. Donor characteristics had no
significant correlation with any of the pharmacokinetic parameters estimated. A fixed dosing regimen of voricon-
azole results in a highly variable exposure of voriconazole in liver transplant patients. Given that trough voricon-
azole concentration is a good measure of drug exposure (AUC), the voriconazole dose can be individualized based
on trough concentration measurements in liver transplant patients.
Due to chronic immunosuppression, infections are common
life-threatening complications in organ transplant patients (7).
Invasive aspergillosis is one of the most dreaded complications
after organ transplantation (21) due to its high mortality rate,
which can range up to 88.1% (18).
Voriconazole (V-Fend [Pfizer]; formerly known as UK-
109496), (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-
4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol, is a novel broad-spectrum
triazole systemic antifungal agent and an ideal drug to prevent
invasive aspergillosis. Compared with other azole antifungal
agents, it has potent activity against a broader spectrum of
clinically significant fungal pathogens, including Aspergillus,
Candida, Cryptococcus neoformans, and some unusual organ-
isms, such as Fusarium and Pseudallescheria boydii (11, 24, 37,
39, 43).
Voriconazole is extensively metabolized hepatically, primar-
ily via the cytochrome P450 (CYP) isoenzymes CYP2C19 and,
secondarily, CYP2C9 and CYP3A4 (15, 25, 39) to inactive
metabolites. Large inter- and intraindividual variabilities in
voriconazole plasma concentrations regardless of the route of
administration or the type of patient population have been
documented and discussed in the literature (2, 17, 19, 22, 23,
33, 38, 40, 42, 45). Factors associated with interindividual vari-
ability of voriconazole exposure include liver dysfunction, al-
cohol abuse in the past (47), concomitant use of potent
CYP450 inducers or inhibitors (10, 12), CYP2C19 genetic poly-
morphisms (including poor as well as ultrarapid metabolizers)
(13, 20, 46), gastrointestinal abnormalities (e.g., mucositis or
diarrhea) (38) impairing drug absorption, and intake with or
without food (15).
Voriconazole is approved at our institution for prophylaxis
in all liver transplant patients. The pharmacokinetics of vori-
conazole in liver transplant patients has not been evaluated,
and there is limited information about the pharmacokinetics of
voriconazole in other solid organ transplant patient popula-
tions (3). We hypothesized that the use of a fixed-dosing reg-
imen of voriconazole would lead to a large degree of variability
in voriconazole exposure in liver transplant patients. Given
that a low voriconazole plasma level of less than 0.25 g/ml is
associated with a poor outcome in patients with aspergillosis
(4, 8, 22, 31, 38, 40) and with ultimately death of the patients,
while a high voriconazole plasma concentration of over 5.5
g/ml is correlated with an increased risk for toxicity, including
visual disturbances, elevated transaminase levels, central ner-
vous system (CNS) disorders (e.g., encephalopathy), and elec-
trolyte disturbances (2, 4, 38, 41), it is important to optimize
the use of voriconazole in this patient population.
The objective of this prospective single-center observational
study was to characterize the pharmacokinetics of voriconazole
in liver transplant patients on a fixed-dose prophylactic regi-
men in order to determine the extent of interpatient variability
in voriconazole exposure among liver transplant patients and
to evaluate the potential correlations between pharmacoki-
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netic parameters and certain patient variables that could po-
tentially explain the large interindividual variability in voricon-
azole pharmacokinetics in liver transplant patients.
MATERIALS AND METHODS
Patients. Between January 2007 and March 2007, liver transplant recipients
who were initiated on a prophylactic voriconazole regimen (200-mg tablets twice
daily orally or via a nasogastric tube) immediately posttransplant as part of their
standard clinical care and who gave informed consent were enrolled in this
prospective study. Children under age 18, patients who were receiving any med-
ications known to influence the pharmacokinetics of voriconazole, and patients
receiving voriconazole to treat an active fungal infection were excluded from this
study. Demographic data, including age, gender, height, weight, race, laboratory
results, and current medication use were recorded. All patients received tacroli-
mus as their primary immunosuppressive agent. The protocol was approved by
the Institutional Review Board at the University of Pittsburgh.
Blood sample collection. Serial blood samples (3 ml) were collected from each
patient just prior to (0 h) and at 0.5, 1, 1.5, 2, 4, 6, 8, and 12 h following
administration of a minimum of five oral doses (range, 5th to 15th dose; mean,
7th dose). Blood samples were collected into heparinized Vacutainer tubes and
centrifuged at 3,000 rpm for 10 min, and plasma was separated and stored at
70°C until analysis.
Genotyping. A 1-ml sample of whole blood was collected and immediately
stored at 80°C for genetic analysis. Additionally, whenever available, allograft
biopsy tissue was also collected and stored at 80°C for future genetic analysis.
Genetic analysis was conducted through isolation of genomic DNA using the
PureGene DNA isolation kit (Gentra Systems, Minneapolis, MN). Determina-
tion of a panel of CYP2C9, CYP2C19, and CYP3A4 and CYP3A5 allelic variants
was performed by TaqMan allele discrimination analyses. The genotyping of
CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C19*3, CYP3A4*1B, CYP3A5*3, and
CYP3A5*6 was performed for all 15 patients (blood) and for 7 donors (liver)
using the Applied Biosystems drug metabolism genotyping assay kits to genotype
for C3608T, A42614C, G19154A, G17948A, A-392G, A6986G, and G14690A,
respectively. Positive and negative PCR controls were included with each am-
plification reaction. Blinded duplicate sample analyses were also performed for
all genotyping assays. An additional 10% of samples were subjected to repeat
analysis to avoid further misclassification and to verify the reproducibility of the
assay. All results were interpreted independently by two laboratory personnel,
and no discordant results were obtained.
Analytical assay. Plasma voriconazole concentrations were measured using a
validated high-pressure liquid chromatography (HPLC) method that was modi-
fied based on previously published assays (9, 26, 27). Sixty microliters of 6%
perchloric acid (Fisher Scientific, Fair Lawn, NJ) was added to 120 l of plasma,
vortexed, and centrifuged (13,000 rpm) for 4 min at room temperature. Fifty
microliters of supernatants was injected onto a HPLC system consisting of a
Waters model 510 HPLC pump, a Waters model 717 plus automatic sampler,
and a Waters model 2487 UV tunable absorbance detector set to 255 nm.
Separation was performed at ambient temperature on a 5-m, 4.6- by 250-mm
Waters C18 symmetry analytical column. The mobile phase consisted of HPLC-
grade acetonitrile and water (68:32, vol/vol; Fisher Scientific, Fair Lawn, NJ).
The total run time was 10 min at a flow rate of 0.8 ml/min. Chromatographic data
were collected and analyzed using Empower chromatography software (Waters,
version 5.0). The assay precision (intraday variability) was 1.3% to 9.0% (0.2 to
9 g/ml), and the assay bias (interday variability) was 0.7% to 3.1% (0.5 to 9
g/ml). The linearity range was 0.2 to 9 g/ml (r2  0.9998).
Pharmacokinetic analysis. Various pharmacokinetic parameters were calcu-
lated using noncompartmental analysis with WinNonlin software (version 4.1;
Pharsight Corporation, Mountain View, CA). The parameters calculated after
enteral administration of voriconazole included the terminal disposition rate
constant (z), terminal disposition half-life (t1/2), area under the curve (AUC),
apparent systemic clearance over bioavailability (CL/F), apparent steady-state
volume of distribution over bioavailability (Vss/F), mean residence time (MRT),
peak concentration in plasma (Cmax), time to reach peak concentration (Tmax),
last concentration in plasma at 12 h (Clast), and area under the first moment of
the concentration-time curve (AUMC). z and t1/2 were derived from data points
during the terminal disposition phase only when at least three data points were
available, and the AUC0- and AUMC0- specific for the dose evaluated were
calculated using the reverse superposition principle. The projected trough vori-
conazole plasma concentration (Clast) was used for three patients (no. 11, 15, and
16) because Clast was missing for these three patients. Each of these parameters
is presented as mean and standard deviation. Statistical comparison of different
parameters was made using a paired two-tailed Student t test (SPSS software,
Windows-based version 14.0; SPSS, Chicago, IL). A P value of 0.05 was con-
sidered statistically significant.
Statistical analysis. The relationship between various pharmacokinetic para-
meters and patient variables and biochemical indices was examined by simple
linear regression analysis. A relationship was considered to be statistically sig-
nificant at a P value of 0.05 for the deviation of the coefficient from zero in the
linear regression analysis. The difference between trough concentrations (C0 and
C12) was tested using a paired two-tailed Student t test. The effect of dichoto-
mous variables (such as gender, race, and concomitant medication) on various
pharmacokinetic parameters of voriconazole was tested using an unpaired two-
tailed Student t test except, for the effect of the CYP2C19 genotype, which was
tested using an unpaired one-tailed Student t test since carriers of CYP2C19*2
and CYP2C19*3 alleles have been identified as poor metabolizers (20). The effect
of feeding methods on various pharmacokinetic parameters of voriconazole was
tested using one-way analysis of variance (ANOVA). A P value of 0.05 was
considered to be statistically significant in all the statistical tests. The relationship
between CL/F, Vss/F, and body weight were evaluated using both a simple linear
model and an allometrical model, parameter  A  (WT/WT)B, where para-
meter includes CL/F and Vss/F, WT denotes actual body weight, and A and B are
coefficients and exponents to be estimated using nonlinear regression.
The 95% confidence bands and 95% prediction bands were calculated and
plotted using GraphPad Prism (version 4.03; GraphPad Software, Inc.) to eval-
uate the precision of parameter estimation and predictive performance.
RESULTS
A total of 15 patients were enrolled in this study. The char-
acteristics of the patients, including the primary diagnosis, days
posttransplantation on the day of study, methods of feeding at
time of study, concomitant medications, MELD (model for
end-stage liver disease) score, age, gender, and race; the char-
acteristics of the donors, including the cold ischemic time,
warm ischemic time, age distribution, and type of liver dona-
tion; the laboratory biochemical and hematological profiles
of the study patients before transplantation and on the day of
pharmacokinetics study; and the pharmacogenomic profiles of
patients and donors are shown in Table 1.
The mean and individual plasma concentrations of voricon-
azole over time after enteral voriconazole administration are
shown in Fig. 1. Among all 15 patients who completed the
study, one patient (no. 13) had an undetectable concentration
of voriconazole in all of the samples and could not be evalu-
ated (no particular reason was identified); three patients (no.
1, 3, and 7) had extremely atypical profiles with fewer than
three data points during the terminal disposition phase, and
noncompartmental pharmacokinetic analysis could there-
fore not be readily performed. Complete pharmacokinetic
data could be calculated for 11 patients. The pharmacoki-
netic parameters of voriconazole after enteral administra-
tion are shown in Table 2. There was a wide variation in
various pharmacokinetic parameters of voriconazole in liver
transplant patients after enteral voriconazole administration
(Fig. 1).
The trough concentrations prior to dosing (C0) and at 12 h
after dosing (C12) are not significantly different (P  0.2794),
and the difference between the trough concentrations (C12 
C0)/C12 averaged 6.4%, indicating that steady state had been
reached in most of the patients at the time of study. There was
a good correlation (r2  0.75) between the trough voriconazole
plasma concentrations and the corresponding AUC0- (Fig. 2)
(n  11). Thirty-three percent of the patients had a trough
level lower than 1 g/ml, and the rest of the patients had a
trough level of between 1 g/ml and 6 g/ml.
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There were significant correlations between various esti-
mated pharmacokinetic parameters and patient variables and
various biochemical indices (the linear regression coefficient
differed significantly from zero). All of the correlations are
summarized in Table 3 and Fig. 3. The 95% confidence bands
and 95% prediction bands were calculated and plotted (Fig. 3).
The correlation between body weight and the two independent
pharmacokinetic parameters CL/F and Vss/F was very poor
using both simple linear regression (r2  0.1345 for CL/F and
0.0308 for Vss/F) and the principle of allometry (r
2  0.0990 for
CL/F and 0.1350 for Vss/F).
Despite the small number of subjects in this study, the pres-
ence of deficient CYP2C19*2 alleles and race were significantly
associated with some pharmacokinetic parameters of voricon-
azole. Compared to those in homozygous extensive metaboliz-
ers (CYP2C19*1/*1), Cmax, Clast, AUMC0-, and MRT0- were
significantly higher in heterozygous extensive metabolizers
(CYP2C19*1/*2), i.e., by 1.9-fold, 2.0-fold, 5.1-fold, and 3.9-
fold, respectively. Compared to that in Caucasian patients (n
9), Tmax was significantly higher (P  0.016), by 3-fold, and
Cmax was significantly lower (P  0.0402), by 2.6-fold, in Asian
patients (n  2) (Table 3). In addition, Vss/F was 2.1-fold
higher (P  0.0513), CL/F was 2.5-fold higher (P  0.1023),
and AUC0- was 2.7-fold lower (P  0.0711) in Asian patients
than in Caucasian patients, although these differences did not
reach statistical significance.
Interestingly, concomitant treatment with pantoprazole and
oral voriconazole was associated with a statistically significant
decrease in voriconazole exposure. The voriconazole half-life,
Cmax, Clast, AUC0-, MRT0-, and AUMC0- were significantly
lower, by 37% to 70%, in patients receiving concomitant pan-
toprazole treatment compared than in those not on pantopra-
zole (Table 3). The CL/F was 3.5-fold higher in patients on
concomitant pantoprazole treatment than in those not on pan-
toprazole, although this difference did not reach statistical
significance (P 0.0533). Feeding methods (regular diet, clear
liquids, or tube feedings) had no effect on the pharmacokinetic
parameters of voriconazole.
It is also worth mentioning that all of the donor variables,
including cold ischemic time, warm ischemic time, donor age,
and type of liver donation, poorly correlated with all of the
estimated pharmacokinetic parameters (r2  0.4).
TABLE 1. Characteristics of patients and donors
Characteristica Valueb
Gender (no. male/no. female) ............................................................................................................. 11/4
No. with diagnosis:
Viral hepatitis (HBV/HCV)............................................................................................................. 1/5
HCV  alcohol.................................................................................................................................. 2
Nonalcoholic steatohepatitis ............................................................................................................ 3
Primary sclerosing cholangitis.......................................................................................................... 2
Autoimmune hepatitis ...................................................................................................................... 1
Wilson’s disease ................................................................................................................................. 1
MELD scorec ......................................................................................................................................... 20.6 	 11.3 (8–43)
Age (yr) .................................................................................................................................................. 56.3 	 10.3 (41–76)
Wt (kg) ................................................................................................................................................... 84.1 	 17.7 (56–121)
Race (Caucasian/Asian) ....................................................................................................................... 13/2
Days posttransplantation on day of study .......................................................................................... 3.7 	 1.4 (2–7)
Feeding at time of study (tube/clear liquid/regular food) ............................................................... 3/11/1
Anastomosis (T-tube present/T-tube absent/Roux-en-Y)d .............................................................. 6/8/1
Concomitant drug (pantoprazole/famotidine) ................................................................................... 10/5
Cold ischemic time (min)..................................................................................................................... 538.9 	 266.6 (86–935)
Warm ischemic time (min) .................................................................................................................. 27.2 	 5.1 (16.8–37.8)
Donor age (yr)....................................................................................................................................... 47.9 	 21.6 (14–84)
Cadaveric/Living donor (n) .................................................................................................................. 13/2
Total bilirubin (mg/dl) .......................................................................................................................... 6.4 	 5.9 (1.9–25.4)/6.1 	 6.4 (0.5–22.9)
AST (U/liter) .........................................................................................................................................1,088.9 	 726.2 (180–2405)/294.8 	 204.2 (33–620)
ALT (U/liter) ......................................................................................................................................... 682.6 	 444.8 (144–1569)/346.1 	 263.4 (53–792)
INR ......................................................................................................................................................... 1.76 	 0.35 (1.1–2.3)/1.3 	 0.16 (1–1.6)
SCr (mg/dl)†........................................................................................................................................... 1.6 	 0.8 (0.6–2.9)/1.7 	 1.3 (0.5–5.2)
Baseline plasma albumin (g/liter)........................................................................................................ 3.1 	 0.5 (2.3–4.1)
CYP2C9*2 (C3608T)............................................................................................................................. 15:0:0 (6:1:0)
CYP2C9*3 (A42614C) .......................................................................................................................... 12:3:0 (5:2:0)
CYP2C19*2 (G19154A) ........................................................................................................................ 12:3:0 (6:1:0)
CYP2C19*3 (G17948A) ........................................................................................................................ 15:0:0 (6:0:0)
CYP3A4*1B (A-392G) .......................................................................................................................... 15:0:0 (6:0:0)
CYP3A5*3 (A6986G) ............................................................................................................................ 0:0:15 (7:0:0)
CYP3A5*6 (G14690A) .......................................................................................................................... 15:0:0 (7:0:0)
a HBV, hepatitis B virus; ALT, alanine aminotransferase; SCr, serum creatinine.
b Values are expressed as mean 	 standard deviation (range) and were measured for patients unless specified as measurements for donors. For bilirubin, AST, ALT,
INR, SCr, and plasma albumin, values are displayed as baseline measurement/measurement on the day of study. For the CYP3 alleles, the donor genotype (liver) is
given in parentheses. The three values displayed represent wild-type homozygous extensive metabolizers (/):heterozygous extensive metabolizers (/):poor
metabolizers (/).
c MELD (model for end-stage liver disease) score  3.78(ln serum bilirubin 
mg/dl)  11.2(ln INR)  9.57(ln serum creatinine 
mg/dl)  6.43.
d Duct-to-duct anastomosis; the T-tube had been removed from some of the patients at the time of study.
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DISCUSSION
Limited pharmacokinetic data on voriconazole in transplant
patients exist in the literature. To date this is the first study to
evaluate the pharmacokinetics of voriconazole in liver trans-
plant patients.
This study involved intense blood sampling (nine data points
for each patient in a single dosing interval) in the immediate
posttransplant period (within 7 days) in a small group of rel-
atively homogenous liver transplant patients (n  15). The
pharmacokinetic profiles of voriconazole are characterized by
an early and sharp increase of voriconazole concentration, with
the peak concentration being reached around 1 to 2 h after
dosing. These profiles were consistent with rapid absorption of
voriconazole. This observation is similar to what has been
reported for nontransplant patients (30).
Despite the relative homogeneity of the population studied, a
large interindividual variability both in plasma concentrations of
voriconazole over time and in individual pharmacokinetic para-
meters calculated using a noncompartmental model has been
demonstrated. In fact, the existence of large inter- and intraindi-
vidual variabilities in voriconazole plasma levels regardless of the
route of administration or the type of patient population has been
widely discussed (2, 17, 19, 22, 23, 33, 38, 40, 42, 45). Studies with
healthy volunteers revealed a 90 to 100% variation in exposure
with a fixed-dose voriconazole regimen. Unpublished results from
our research group have shown that nearly 15.2% of the patients
on recommended doses do not have any measurable trough
plasma concentration, and nearly 42.5% of the patients have
trough plasma concentrations of less than 1 g/ml (our clinical
observations). We have observed a 35-fold variation in exposure
as indicated by the area under the plasma concentration-time
curve (AUC) among lung transplant patients receiving a fixed-
FIG. 1. (a) Plasma concentration profiles of voriconazole during one dosing interval. Large interindividual variability can be observed. Patients
1, 3, 7, and 13 had extremely atypical profiles. (b) Mean (	 standard deviation) plasma concentrations of voriconazole during one dosing interval,
with patients 1, 3, 7, and 13 excluded (see text).
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dose prophylactic regimen (3). Factors associated with interindi-
vidual variability of voriconazole exposure have been suggested to
include liver dysfunction or alcohol abuse in the past (47), con-
comitant use of potent CYP450 inducers or inhibitors (10),
CYP2C19 genetic polymorphisms including poor as well as ultra-
rapid metabolizers (13, 20, 46), and intake with or without food
(15).
The large variability observed in liver transplant patients
may be explained by variations in absorption, elimination and
drug-drug interactions. Variability in absorption with oral vori-
conazole administration may cause the large interindividual
variability of voriconazole exposure. First, a decrease in the
motility of the gastrointestinal tract after liver transplant sur-
gery is a common physiological change that is unique to this
patient population. The magnitude of the decrease in the gas-
trointestinal motility is quite different from patient to patient
and therefore may be a source of variability and could poten-
tially alter the rate of absorption of voriconazole. Second,
voriconazole is highly lipophilic, and therefore its absorption is
likely dependent on secretion of bile. Variation in bile flow
between patients and variable dissolution of voriconazole may
be another source of variability and could potentially lead to
altered bioavailability. Finally, administration of voriconazole
with food has a significant influence on voriconazole absorp-
tion, and therefore the feeding method is also a source of
variability. Although this study involved only enteral adminis-
tration of voriconazole and bioavailability could not be esti-
mated, unpublished results from our research group have
shown that voriconazole bioavailability varied from 57% to
94% in lung transplant patients.
Variability in elimination may be another factor responsible
for the large interindividual variability of voriconazole expo-
sure. First, the most relevant physiological factor that can lead
to the large variability of voriconazole exposure may be the
differences in liver function caused by physiological character-
istics unique to this patient population, because voriconazole is
extensively metabolized in the liver, with less than 2% of the
administered dose being excreted unchanged in urine and fe-
ces (28, 29, 30, 36). There are no clinically relevant effects of
renal impairment on the pharmacokinetic profile of oral or
intravenous voriconazole (28, 29, 30). Second, voriconazole
has demonstrated nonlinear pharmacokinetics due to satura-
TABLE 2. Pharmacokinetic parameters of voriconazole after enteral administrationa
Patient z (h) t1/2 (h) Tmax (h) Cmax (g/ml)
Clast
(g/ml)b
AUC0-
(h  g/ml)
AUMC 0-
(h  h  g/ml) V/F (liters)
CL/F
(liters/h) MRT0- (h)
2 0.04 16.1 1.1 2.6 1.6 34.3 1,662.8 81.1 3.5 48.5
4 0.12 5.6 2.1 3.5 0.6 15.2 145.7 76.8 9.5 9.6
5 0.07 9.5 2.0 0.9 0.4 7.2 182.9 239.1 17.5 25.4
6 0.02 30.0 1.0 5.4 3.3 37.7 12,945.6 46.0 1.1 343.5
8 0.07 9.4 6.1 1.6 1.0 14.7 480.2 89.7 6.6 32.7
10 0.05 14.9 2.1 4.1 2.5 38.1 2,610.8 45.3 2.1 68.6
11 0.04 17.8 0.5 3.1 1.52 27.9 2,089.1 82.4 3.2 74.9
12 0.04 15.5 1.2 4.0 1.8 34.4 1,940.9 63.6 2.8 56.3
14 0.09 7.4 1.5 1.4 0.4 9.2 135.5 165.2 15.5 14.8
15 0.03 21.3 2.3 3.2 2.08 45.7 3,826.1 65.8 2.1 83.7
16 0.04 17.7 0.5 2.4 1.49 20.6 2,113.1 84.8 3.3 102.4
Mean 0.06 15.0 1.8 2.9 1.6 25.9 2,557.5 94.5 6.1 78.2
SD 0.03 7.0 1.5 1.3 0.9 13.1 3,643.6 57.6 5.7 92.7
Coefficient of
variation (%)
52.69 46.6 84.8 45.4 58.3 50.7 142.5 61.0 92.6 118.6
Median 0.04 15.5 1.5 3.1 1.7 27.9 1,940.9 81.1 3.3 56.3
95% Confidence
interval
0.04–0.08 10.9–19.1 0.9–2.74 2.1–3.7 1.0–2.1 18.1–33.7 404.3–4,710.7 60.5–128.6 2.8–9.5 23.4–133.0
a Cmax, maximum concentration; Tmax, time to reach maximum concentration; Clast, concentration at 12 h; z, disposition rate constant; t1/2, apparent half-life;
AUC0-, area under the concentration-time curve 0 h to infinity; CL/F, clearance/bioavailability; V/F, volume of distribution/bioavailability; MRT0-, mean residence
time; AUMC0-, area under the first moment of the concentration-time curve from 0 h to infinity.
b The Clast values for patients 1, 3, 7, and 13 were 3.07 g/ml, 1.6 g/ml, 0.76 g/ml, and 0 g/ml (unmeasurable), respectively. Projected Clast values for patients
11, 15, and 16 were used (see text).
FIG. 2. Correlation between AUC0- and trough concentrations
(C12). Main figure, r
2  0.745% when AUC0- and trough concentra-
tions are correlated for all 11 patients who had typical profiles. Inset,
r2  0.852% when AUC0- and trough concentrations are correlated
for 10 patients who had typical profiles, with patient 6 omitted.
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tion of metabolism (28, 29, 30), especially in patients with
decreased liver function. Voriconazole metabolism may be sat-
urated in some patients. Finally, genetic polymorphism of
CYP2C19 (encoding the major metabolizing enzyme for vori-
conazole) among patients can result in interindividual variabil-
ity in metabolism (28, 29, 30, 13, 20, 46).
Potential drug-drug interactions may also contribute to the
large interindividual variability of voriconazole exposure.
Transplant patients simultaneously receive many therapeutic
agents for treatment and prophylaxis. In vitro studies have
shown that voriconazole has the greatest affinity for CYP2C19,
lower affinity for CYP2C9, and limited affinity for CYP3A4
(28, 29, 30). Inhibitors and/or inducers of these enzymes may
change the pharmacokinetics of voriconazole (28, 29, 30), but
in this study, patients were not receiving any drugs known to be
inhibitors or inducers of voriconazole metabolism.
It is important to identify patient factors that significantly
contribute to this large inter- and intraindividual variability by
exploring the correlations between pharmacokinetic parame-
ters (especially drug exposure) and patient variables. This is
particularly true for voriconazole, because simple efficacy mea-
sures for molds, to which the patient dose can be titrated, are
not yet available. So far there have been only animal model
data for Candida showing a predictive pharmacodynamic pa-
rameter (AUC/MIC) as a potential target value (1), with no
equivalent data for molds. However, there is a simple
HPLC/UV assay available to monitor voriconazole levels. In
this study we have observed that patients with higher total
bilirubin, international normalized ratio (INR), and aspartate
transaminase (AST), which are indicative of hepatic dysfunc-
tion and hepatocellular injury, had higher voriconazole expo-
sure, characterized by a lower z (elimination rate constant),
higher half-life, higher AUC0-, and lower CL/F. We have also
identified a positive association between the hours posttrans-
plantation and voriconazole exposure, characterized by an in-
creased half-life, Cmax, Clast, AUC0-, AUMC0- and MRT0-.
This suggested an increase in voriconazole exposure with in-
creased time posttransplantation.
The reason why poor (good) hepatic function is associated
with a low (high) elimination rate constant, long (short) half-
life, high (low) AUC0-, and low (high) CL/F of voriconazole is
very likely that voriconazole is extensively metabolized in the
liver, with less than 2% of the administered dose excreted
unchanged in urine and feces (28, 29, 30, 36).
Voriconazole is a low- to intermediate-clearance drug. Vori-
conazole clearance is highly variable in different studies, rang-
ing from 15 to 35.25 liters/h (14, 17, 28, 29, 30, 33, 35, 42), and
oral clearance of voriconazole varies from 8.1 to 23.4 liters/h
(16, 32, 34). Therefore, the hepatic extraction ratio should
range from 0.09 to 0.39. For a low-clearance drug CLapparent 
fraction unbound  intrinsic clearance. The fraction unbound
depends on the liver function of the patient. Therefore, pa-
tients with higher total bilirubin, INR, and AST, indicative of
hepatic dysfunction and hepatocellular injury, had higher vori-
conazole exposure and a lower CL/F.
The reason for the positive association between the time
posttransplantation and voriconazole exposure as character-
ized by increased Cmax, Clast, and AUC0- is likely to be an
increased bioavailability over time after transplantation. It has
been observed in clinical settings that gastrointestinal motility
is decreased immediately after transplantation surgery and is
recovered gradually. Although the hepatic surgical damage is
recovered and hepatic function is improved after transplanta-
tion, which could lead to increased metabolism and decreased
exposure of voriconazole, recovery in gastrointestinal motility af-
ter the transplantation surgery is likely to contribute to a greater
TABLE 3. Correlations between estimated pharmacokinetic parameters and patient variables
Patient variablea
Correlationb with:
 t1/2 Tmax Cmax Clast AUC0- V/F CL/F AUMC0- MRT0-
HPT 0.7415 () 0.6132 () 0.6256 () 0.4564 () 0.7444 () 0.7004 ()
ASTo 0.4395 ()
Bild 0.4746 ()
INRo 0.6510 () 0.4214 () 0.4490 ()
INRd 0.5639 () 0.4555 ()
RACE 0.016 0.0402 0.0711 0.0513 0.1023
PAN 0.0066 0.0112 0.0939 0.0629 0.0868
T-tube 0.0841
CYP2C19 0.0136 0.0352 0.0131 0.0154
a HPT, hours posttransplantation; ASTo, baseline AST; Bild, total bilirubin on day of study; INRo, baseline international normalized ratio; INRd, international
normalized ratio on day of study; PAN, pantoprazole; T-tube, T-tube present or absent at time of study; CYP2C19, heterozygous extensive metabolizers (CYP2C191/2).
b For HPT, ASTo, Bild, INRo, and INRd, r2 for linear regression between the two variables is shown, and symbols in parentheses indicate a positive () or negative
() association. For RACE, PAN, T-tube, and CYP2C19, the P value is shown.
FIG. 3. Correlation between time (hours) posttransplantation and
trough plasma concentrations of voriconazole for all 11 patients who
had typical profiles.
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extent, resulting in increased exposure to voriconazole (Cmax and
Clast). In addition, increased bile production and secretion may
also contribute to an increased exposure to voriconazole.
A decreased unbound fraction in the blood caused by in-
creased plasma protein synthesis with recovered hepatic func-
tion is not very likely to be responsible for the positive associ-
ation between the time posttransplantation and voriconazole
exposure because voriconazole is not very extensively bound to
plasma proteins in blood, with an unbound fraction of less than
0.42 (28, 29, 30).
The presence of CYP2C19*2 alleles resulted in a higher
Cmax, Clast, AUMC0-, and MRT0-. This observation in this
study is in accordance with recently published data obtained
with healthy volunteers (13, 20, 46). It has been reported that
voriconazole exposure (AUC) is increased by 4-fold in poor
metabolizers compared to homozygous extensive metabolizers.
Nearly 15 to 20% of Asians and 3 to 5% of Caucasians are poor
metabolizers (28, 29, 30). There is also an average 2-fold in-
crease in exposure to voriconazole in heterozygous versus ho-
mozygous extensive metabolizers (28, 29, 30). The presence of
deficient activity of CYP2C19*2 alleles resulted in higher Cmax,
AUMC0-, and MRT0-. However, the CYP2C19 genetic anal-
ysis in this study did not include the newly identified excessive
allele CYP2C19*17 (ultrarapid metabolizer) (46) and included
only the deficient alleles CYP2C19*2 and CYP2C19*3, which
account for more than 85% of defective CYP2C19 alleles in
Caucasians (5). Therefore, the existence of excessive alleles
and other defective alleles, and thus misclassification of pa-
tients, cannot be ruled out.
The possible effect of race on the pharmacokinetics of voricon-
azole observed in this study has never been reported before. It
seems that Asian patients have a slower absorption process than
Caucasian patients, characterized by a higher Tmax and lower
Cmax, but this remains to be further investigated.
In addition, the possible effect of coadministered pantopra-
zole on the exposure of voriconazole might be due to de-
creased absorption of voriconazole caused by proton pump
inhibition, since it has been reported that pantoprazole causes
no apparent induction or inhibition of cytochrome P450 en-
zyme systems (28, 29, 30). Pantoprazole sodium is a proton
pump inhibitor (PPI) that covalently binds to the (H,K)-
ATPase enzyme system at the secretory surface of the gastric
parietal cell. This action suppresses the final step in gastric acid
production and leads to inhibition of both basal and stimulated
acid secretion. Pantoprazole produces extensive and long-last-
ing inhibition of gastric acid secretion. PPI agents may reduce
absorption of azoles by increasing gastric pH. However, this
explanation is also questionable, because significant decrease
in voriconazole exposure due to decreased absorption caused
by proton pump inhibition has never been reported. In con-
trast, the PPI agent omeprazole has been reported to cause an
increase in voriconazole exposure due to inhibition of metab-
olizing enzyme (28, 29, 30, 48). Therefore, further investigation
is required to make any conclusion about the effect of coad-
ministered pantoprazole on the exposure of voriconazole.
Donor characteristics have been shown to have no effect on
voriconazole pharmacokinetics in this study. If this observation
is unbiased, the current voriconazole dosing regimen for liver
transplant patients, without consideration of donor character-
istics, should be an adequate dosing strategy. However, it is
important to point out that exclusion of a factor does not
necessarily mean that this covariate has no significant influence
on the pharmacokinetic parameters, especially in this study
with a small homogeneous group of patients in the immediate
posttransplant period. There can be many reasons for exclu-
sion of donor characteristics as a significant factor for voricon-
azole pharmacokinetics in this study. First, some of the donor
characteristics are not variable in the population studied. Sec-
ond, simple linear regression is not an adequate model to
assess the correlation between donor characteristics and vori-
conazole pharmacokinetics. Third, some of the donor charac-
teristics may have significant effects on voriconazole pharma-
cokinetics only when their values are above (or below) a
certain threshold value. If the values of these donor character-
istics in this study were all below (or above) this threshold
value, these donor characteristics would be excluded as a sig-
nificant factor influencing voriconazole pharmacokinetics, no
matter how variable this covariate is. Finally, some of the
donor characteristics may have significant effects on voricon-
azole pharmacokinetics only when evaluated with interaction
and coeffects with other patient/donor factors together. When
evaluated alone without interaction with other factors, a sig-
nificant factor could be identified as insignificant, which is a
limitation of this study that will be discussed below. Therefore,
further investigation of the effects of donor characteristics on
voriconazole pharmacokinetics is required.
A large variability in voriconazole exposure following a fixed
dosing regimen necessitates individualizing voriconazole dos-
ing to maximize therapeutic efficacy and minimize toxicity in
liver transplant patients, especially considering that 33.3% of
the patients in this study had a trough level below 1 g/ml.
There is no simple efficacy measure to which the patient dose
can be titrated, but there is a simple HPLC/UV assay available
to monitor voriconazole levels. Therapeutic monitoring may be
important in optimizing therapy with this drug, which has been
proposed (2, 4, 6, 44) and is currently performed in the routine
clinical monitoring program at our institution, with a target
trough concentration of 1 g/ml to 6 g/ml. However, trough
plasma concentrations have never been documented as surro-
gate markers of voriconazole exposure in liver transplant re-
cipients. The good correlation (r2  0.85) observed in this
study between the trough voriconazole plasma concentrations
and the corresponding AUC0- (Fig. 2 [n  10]) indicates that
trough voriconazole concentration is a good measure of vori-
conazole exposure (AUC) in patients.
These findings are likely to be clinically relevant because
they suggest that the voriconazole dose should be relatively
high immediately after transplantation, especially in patients
with good liver function as measured by low AST, total biliru-
bin, or INR, in order to avoid ineffectiveness of prophylaxis/
treatment and its consequences (fungal infections, especially
invasive aspergillosis). It has been reported that a low voricon-
azole exposure of 0.25 or 1 g/ml is associated with a poor
outcome in patients with aspergillosis (4, 8, 22, 31, 38, 40) and
in ultimately death of the patients. The voriconazole dose
should be then gradually reduced, especially in patients with poor
liver function as defined by high AST, total bilirubin, or INR, in
order to avoid toxicity caused by high voriconazole exposure. It
has been reported that high voriconazole plasma concentrations
(5.5 g/ml) are correlated with an increased risk for toxicity,
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including elevated transaminase levels, CNS disorders (e.g., en-
cephalopathy), and electrolyte disturbances (2, 38, 41).
In conclusion, this study has demonstrated that there is a
large interindividual variability in the pharmacokinetics of
voriconazole in liver transplant patients. A fixed dosing regi-
men leads to widely variable exposure of voriconazole in liver
transplant patients. Donor characteristics seem to have no
significant influence on voriconazole pharmacokinetics, but
further investigation is required due to the small number of
subjects evaluated in this study. Postoperative time and poor
liver function are positively associated with voriconazole expo-
sure and half-life, which may be useful for dosage adjustment.
CL/F and Vss/F are not correlated with body weight, which
does not support a weight-based dosing strategy. The trough
concentration is a good measure of voriconazole exposure
(AUC0-) and should be used in practice to individualize vori-
conazole dosage.
A fixed dosing regimen is not optimal for voriconazole ther-
apy for prophylaxis and treatment in liver transplant patients.
This evaluation will allow for an assessment of the adequacy of
the prophylactic regimen in achieving therapeutic drug con-
centrations in all subjects and could potentially help identify
patients at risk for extremes in voriconazole exposure.
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